Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-07-03
2007-07-03
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S015800, C514S016700, C514S017400, C514S018700, C530S300000, C530S327000, C530S328000, C530S329000, C530S330000, C530S331000
Reexamination Certificate
active
08452098
ABSTRACT:
The present invention relates to a method for inhibiting the adhesion of one cell to another comprising interfering with the interaction between the extracellular matrix receptor and its ligand.The invention is based upon the discovery that the α4β1 extracellular matrix receptor promotes adhesion of lymphocytes to endothelial cells via attachment to a defined peptide sequence. Prior to the present invention, the ligand of the α4β1 receptor had not been identified, nor had the function of the α4β1 receptor in lymphocyte attachment been known. By preventing the interaction between the α4β1 receptor and its ligands using antibodies or defined peptide sequences, the present invention enables, for the first time, specific intervention in the migration of lymphocytes through the vascular endothelium and into tissues. The present invention, therefore, has particular clinical utility in suppression of the immune response; in various specific embodiments of the invention, the adherence of lymphocytes to endothelium may be inhibited systemically, or may, alternatively, be localized to particular tissues or circumscribed areas. Accordingly, the present invention provides for treatment of diseases involving autoimmune responses as well as other chronic or relapsing activations of the immune system, including allergy, asthma, and chronic inflammatory skin conditions.
REFERENCES:
patent: 4412990 (1983-11-01), Lundblad et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4879237 (1989-11-01), Rudslahti et al.
patent: 5217870 (1993-06-01), Hession et al.
patent: 5229366 (1993-07-01), Tsukada et al.
patent: 5340727 (1994-08-01), Ruggeri et al.
patent: 5403919 (1995-04-01), Butcher
patent: 0 330 506 (1989-08-01), None
patent: WO 90/07321 (1990-07-01), None
patent: WO 90/08833 (1990-08-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 91/03252 (1991-03-01), None
Sherman-Gold et al. Genetic Engineering News 13(3) G, I, 14 (1993).
Hamann et al. J. Immunol. 152: 3282-3293 (1994).
Algel Da et al. Faseb J. 8: 504-512 (1994).
Ager et al. Int. Immunol. 2: 921-938 (1990).
Kogan et al. J Biol Chem. 270:14047-14055 (1995).
Rozdzinski et al. J. Infect. Diseases 168:1422-1428 (1993).
Ngo et al. In The Protein Folding Problem and Tertiary Structure Prediction. Merz and Le Grand(eds) Birkhauser Boston 1994, pp. 491-495.
Kuntz Science 257: 1078-1082 (1992).
Skolaack et al. Trends in Biotech 18:34-39 (2000).
Wayner et al., J. Cell Biol. 116:489-497,1992.
Dustin, M.L., et al., Lymphocyte Function-associated Antigen-1 (LFA-1) Interaction with Intracellular Adhesion Molecule 1 (ICAM1) is One of at Least Three Mechanisms for Lymphocyte Adhesion to Cultured Endothelial Cells,J. Cell Biol.,107, pp. 321-333 (1988).
Harlan, Leukocyte-Endothelial Interactions,Blood, 65, pp. 513-525 (1985).
Knapp, Leukocyte Typing IV: White Cell Differentiation Antigens, 1989 Inst. for Immunology, University of Vienna 1087.
Marcantonio, E.E., et al., Antibodies to the Conserved Cytoplasmic Domain of the Integrin β-1 Subunit React With Proteins in Vertebrates, Invertebrates and Fungi,J. Cell Biol., 106, pp. 1765-1772 (1988).
Osbørn, L. et al., Direct Expression Cloning of Vascular Cell Adhesion Molecule 1, a Cytokeine-Induced Endothelial Protein That Binds to Lymphocytes,Cell, 59, pp. 1203-1212 (1989).
Ruoslahti, Fibronectin and Its Receptors,Am. Rev. Biochem., 57, pp. 375-413 (1988).
Takada, Y., et al., The Primary Structure of the VLA-2/Collagen Receptor α2Subunit (Platelet GPIa): Humology to Other Integrins and the Presence of a Possible Collagen-binding Domain,J. Cell Biol., pp. 397-407 (1989).
Lobb, R.R., et al., The Pathophysiologic Role of α4Integrins In Vivo,J. Clin. Invest.,94, pp. 1722-1728, 1994.
Carlos, T.M., et al., Leukocyte-Endothelial Adhesion Molecules,Blood, 84(7):2068-2101, 1994.
Holzmann, B., et al., Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with an α Chain Homologous to Human VLA-4α,Cell, 56:37-47, 1989.
Liao et al., Exp. Cell Res. 181:348-361, 1989.
Wayner et al., J. Cell Biol. 107:1881-1891, 1988.
Humphries et al., J. Cell Biol. 106:1289-1297, 1988.
Wayner and Carter, J. Cell Biol. 105:1873-1884, 1987.
Hemler et al., J. Biol. Chem 262:11478-11485, 1987.
Bernardi et al., J. Cell Biol. 105:489-498, 1987.
Humphries et al., J. Biol. Chem. 262:6886-6892, 1987.
Haynes, Cell 48:549-554, 1987.
Humphries et al., J. Cell Biol. 103:2637-2647, 1986.
Giancotti et al., J. Cell Biol. 103:429-437, 1986.
Kornblihtt et al., EMBO J. 4:1755-1759, 1985.
Pierschbacher and Ruoslahti, Nature 309:30-33, 1984.
Jalkanen, S., et al., Homing receptors and the control of lymphocyte migration, Immunological Reviews 91:39-60, 1986.
Gallatin, W.M., et al., A cell-surface molecule involved in organ-specific homing of lymphocytes, Nature 304:30-34, 1983.
Gallatin, W.M., et al., Lymphocyte homing receptors, Cell 44:673-680, 1986.
Woodruff, J.J., et al., Specific cell-adhesion mechanisms determining migration pathways of recirculating lymphocytes, Annual Review of Immunology 5:201-222, 1987.
Springer, T.A., et al., The lymphocyte function-associated LFA-1, CD2 and LFA-3, molecules: cell adhesion receptors of the immune system, Annual Review of Immunology 5:223-252, 1987.
Butcher, E.C., et al., Organ specificity of lymphocyte migration: mediation by highly selective lymphocyte interaction with organ-specific determinants on high endothelial venules, Journal of Immunology 10:556-561, 1980.
Jalkanen, S., et al. Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man, Journal of Immunology 141:1615-1623, 1988.
Carter, W.G., and E.A. Wayner, Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells, Journal of Biological Chemistry 263:4193-4201, 1988.
Haskard, D., et al. T lymphocyte adhesion to endothelial cells: mechanisms demonstrated by anti-LFA-1 monoclonal antibodies, Journal of Immunology 137:2901-2906, 1986.
Hamann, A., et al., Evidence for an accessory role of LFA-1 in lymphocyte-high endothelium interaction during homing, Journal of Immunology 140:693-699, 1988.
Kupper, T.S., et al., The integrin-binding peptides GRGDSP and GPEILDVPST abrogate T cell mediated immune responses in vivo, Abstract of poster at FASEB meeting, Apr. 23-25, 1991.
Springer, T.A., Adhesion receptors of the immune system, Nature 346:425-434, Aug. 2, 1990.
Bochner, B.S., et al., “Adhesion of Human Basophils, Eosinophils, and Neutrophils to Interleukin 1-activated Human Vascular Endothelial Cells: Contributions of Endothelial Cell Adhesion Molecules,”J. Exp. Med., 173, pp. 1553-1556 (1991).
Burkly, L., et al., “Signaling by Vascular Cell Adhesion Molecule-1 (VCAM-1) Through VLA-4 Promotes CD3-dependent T Cell Proliferation,”Eur. J. Immunol.,21, pp. 2871-2875 (1991).
Damle, N., et al., “Vascular Cell Adhesion Molecule 1 Induces T-cell Antigen Receptor-dependent Activation of CD4+T Lymphocytes,”Proc. Natl. Acad. Sci. USA,88, pp. 6403-6407 (1991).
Dobrina, A., et al., “Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells,”J. Clin. Invest., 88, pp. 20-26 (1991).
Elices, M. J., et al., “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site,”Cell, 60, pp. 577-584 (1990).
Freeman, A., et al., “Adhesion of Human B Cells to Germinal Centers in Vitro Involves VLA-4 and INCAM-110,”Science, 249, pp. 1030-1033 (1990).
Hemler, M. E., et al., “The VLA Protein Family,”J. Biol. Chem.,262(7), pp. 3300-3309 (1987).
Holzmann, B., et al., “Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with an α Chain Homologous to Human VLA-4α,”Cell, 56, pp. 37-46 (1989).
Issekutz, T., “Inhibition of In Vivo Lymphocyte Migration to Inflammation a
Fred Hutchinson Cancer Research Center
Gambel Phillip
Townsend and Townsend / and Crew LLP
LandOfFree
Inhibition of lymphocyte adherence with CS-1-peptides and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of lymphocyte adherence with CS-1-peptides and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of lymphocyte adherence with CS-1-peptides and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3780426